GlaxoSmithKline (LON:GSK)‘s stock had its “market perform” rating reaffirmed by Sanford C. Bernstein in a research note issued on Monday, American Banking News.com reports. They currently have a GBX 1,633 ($26.74) price target on the stock. Sanford C. Bernstein’s price target would indicate a potential upside of 0.90% from the company’s current price.
GlaxoSmithKline (LON:GSK) opened at 1618.925 on Monday. GlaxoSmithKline has a 52-week low of GBX 1327.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1617. and its 200-day moving average is GBX 1651.. The company’s market cap is £77.984 billion.
The company also recently announced a dividend, which is scheduled for Thursday, January 9th. Investors of record on Wednesday, November 13th will be paid a dividend of $19.00 per share. This represents a dividend yield of 1.15%. The ex-dividend date is Wednesday, November 13th.
GSK has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, November 21st. They now have a GBX 1,810 ($29.63) price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, November 19th. They now have a GBX 1,500 ($24.56) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, November 13th. They now have a GBX 1,800 ($29.47) price target on the stock. Five investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of GBX 1,616.42 ($26.46).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.